Literature DB >> 15252148

Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name?

Steven Grant1, Paul Dent.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15252148

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


× No keyword cloud information.
  7 in total

1.  Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.

Authors:  Prithviraj Bose; Edward B Perkins; Connie Honeycut; Martha D Wellons; Tammy Stefan; James W Jacobberger; Emmanouil Kontopodis; Jan H Beumer; Merrill J Egorin; Chiyo K Imamura; W Douglas Figg; Judith E Karp; Omer N Koc; Brenda W Cooper; Selina M Luger; A Dimitrios Colevas; John D Roberts; Steven Grant
Journal:  Cancer Chemother Pharmacol       Date:  2012-02-15       Impact factor: 3.333

2.  Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.

Authors:  Rong Chen; Michael J Keating; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2005-06-21       Impact factor: 22.113

3.  Antitumor effects of flavopiridol on human uterine leiomyoma in vitro and in a xenograft model.

Authors:  Hyun-Gyo Lee; Jong-Woo Baek; So-Jin Shin; Sang-Hoon Kwon; Soon-Do Cha; Won-Jin Park; Rosa Chung; Eun-Som Choi; Gun-Ho Lee; Chi-Heum Cho
Journal:  Reprod Sci       Date:  2014-02-25       Impact factor: 3.060

4.  The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.

Authors:  Paolo Bonvini; Elisa Zorzi; Lara Mussolin; Giovanni Monaco; Martina Pigazzi; Giuseppe Basso; Angelo Rosolen
Journal:  Haematologica       Date:  2009-06-16       Impact factor: 9.941

5.  Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.

Authors:  Beata Holkova; Maciej Kmieciak; E Brent Perkins; Prithviraj Bose; Rachid C Baz; G David Roodman; Robert K Stuart; Viswanathan Ramakrishnan; Wen Wan; Cody J Peer; Jana Dawson; Loveleen Kang; Connie Honeycutt; Mary Beth Tombes; Ellen Shrader; Caryn Weir-Wiggins; Martha Wellons; Heidi Sankala; Kevin T Hogan; A Dimitrios Colevas; L Austin Doyle; William D Figg; Domenico Coppola; John D Roberts; Daniel Sullivan; Steven Grant
Journal:  Clin Cancer Res       Date:  2014-09-23       Impact factor: 12.531

6.  Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.

Authors:  Yun Ge; Jung S Byun; Paola De Luca; Geraldine Gueron; Idalia M Yabe; Sara G Sadiq-Ali; William D Figg; Jesse Quintero; Cynthia M Haggerty; Quentin Q Li; Adriana De Siervi; Kevin Gardner
Journal:  Mol Pharmacol       Date:  2008-06-12       Impact factor: 4.436

7.  Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol.

Authors:  Burak Cem Soner; Huseyin Aktug; Eda Acikgoz; Fahriye Duzagac; Ummu Guven; Sule Ayla; Cag Cal; Gulperi Oktem
Journal:  Int J Mol Med       Date:  2014-09-11       Impact factor: 4.101
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.